Young age does not protect against the adverse effects of reduced ovarian reserve--an eight year study. - Wikidata - awgldk - TriplyDB

Young age does not protect against the adverse effects of reduced ovarian reserve--an eight year study.

Young age does not protect against the adverse effects of reduced ovarian reserve--an eight year study.

http://www.wikidata.org/entity/Q44013160

about

Poor ovarian reserve Management of poor responders in IVF: is there anything new?Total fertilization failure: is it the end of the story?Evaluation of serum anti-Mullerian hormone as a biomarker of early ovarian aging in young women undergoing IVF/ICSI cycle.Live birth and cumulative live birth rates in expected poor ovarian responders defined by the Bologna criteria following IVF/ICSI treatment.Correlation of oocyte morphometry parameters with woman's age.Different ovarian response by age in an anti-Müllerian hormone-matched group undergoing in vitro fertilization.Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing.Single and repeated GnRH agonist stimulation tests compared with basal markers of ovarian reserve in the prediction of outcome in IVF.Selective single blastocyst transfer reduces the multiple pregnancy rate and increases pregnancy rates: a pre- and postintervention study.Activin Decoy Receptor ActRIIB:Fc Lowers FSH and Therapeutically Restores Oocyte Yield, Prevents Oocyte Chromosome Misalignments and Spindle Aberrations, and Increases Fertility in Midlife Female SAMP8 Mice.Corifollitropin α followed by menotropin for poor ovarian responders' trial (COMPORT): a protocol of a multicentre randomised trial.Elevated basal FSH levels, if it is under 15 IU/L, will not reflect poor ART outcomes.Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization Anti Mullerian Hormone: Ovarian response indicator in young patients receiving Long GnRH Agonist Protocol for Ovarian Stimulation.Elevated basal FSH and embryo quality: lessons from extended culture embryos: raised FSH and blastocyst quality.Assessment of ovarian reserve: Anti-Mullerian hormone versus follicle stimulating hormone.Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).Does women's age influence zona pellucida birefringence of metaphase ΙΙ oocytes in in-vitro maturation program?In vitro fertilization outcome in women with diminished ovarian reserve.Is anti-Müllerian hormone associated with IVF outcomes in young patients with diminished ovarian reserve?Gonadotrophin-releasing hormone agonist protocol of controlled ovarian hyperstimulation as an efficient treatment in Bologna-defined poor ovarian responders.Comparison of age-related changes in anti-Müllerian hormone levels and other ovarian reserve tests between healthy fertile and infertile population.Are ART outcomes more successful in younger women? A retrospective study.Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial.Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.Poor ovarian response in patients younger than 35 years: is it also a qualitative decline in ovarian function?Variation in the ovarian reserve is linked to alterations in intrafollicular estradiol production and ovarian biomarkers of follicular differentiation and oocyte quality in cattle.Antral follicle count reliably predicts number of morphologically healthy oocytes and follicles in ovaries of young adult cattle.Antral follicle count as a marker of ovarian biological age to reflect the background risk of fetal aneuploidy.Influence of BMI on risk of miscarriage after single blastocyst transfer.

P2860

Q26744379-C175C6FF-9831-4DB5-B64F-927E00A14B72 Q34022512-0CC6713A-48A6-4FF4-8891-91AEE12960DB Q34145690-C6C637DA-BB27-4328-B30E-6E6973747E83 Q34371743-0C8827F0-96D3-4513-8236-3DC66381F468 Q35154524-34CC835E-238C-4DFC-9428-59E1D2D4F748 Q35171093-11C9F283-8DE7-4153-BBDC-34CFE545A5F2 Q35722615-7A92F1F6-DD85-4B35-A6BF-C3E2162AA68D Q35966481-18A5D63D-F507-4262-A5CE-64F61CADC0DC Q36270584-28AAB65F-5537-415D-B6A5-5E8F4320D000 Q36477504-AC617526-E0EE-43CB-BA66-CA46C3655717 Q36625099-4D921766-E9E5-49D2-B11A-7AE88C10D054 Q36893583-A74856B6-9F48-4856-9AF6-F6DBBA33C6FC Q36970359-3D78FCF1-A914-4FC2-8AAF-32208CA15269 Q37012942-2430F465-515F-4ACC-92B1-2C7B230D37F9 Q37244112-B0193924-3383-4D1F-8BE2-2F44E676149C Q37313026-EF4C3D76-A5E3-494D-8E5C-4E23C28985AF Q37593698-0F7A4DBA-7A7C-4BDD-93DD-0A12D33708D8 Q37606149-F4F10130-2283-4C7D-BD27-FFF818BE75AF Q37615365-CD42C28A-2D09-4A04-8AA9-3DD7B5D6271A Q37647328-89386B6C-DBEB-49FA-B8A9-5E1D3553349F Q37732167-8CD7F04F-FA06-4F0B-B1E6-CC417C531BE3 Q39825272-274F0E39-ECEB-45FA-86E2-4546AD1584F9 Q42497324-7B202AE7-62F5-4345-AC7D-0BDAD5E676D5 Q43561152-03C3625F-3607-40FA-B448-A5C9D138DECF Q45182687-9484C94F-D180-497C-9CC1-C64FBA9D76CD Q45234419-E92C66DA-1FB5-4E6D-AC2F-D894E11DE7A4 Q45959530-38CECB62-4C42-4766-90EF-2F63A341C81D Q46151084-5DB8150D-DF34-40B8-B9FE-31B13F247C85 Q46392000-B49A57EC-A90C-4521-9A66-BE303DDDADB7 Q48605261-29AF2020-9F9C-4ABF-ADD0-09AB1EE038C9 Q51430201-C6C4A006-B7B3-4879-8F8E-169F6B3172EA

P2860

Young age does not protect against the adverse effects of reduced ovarian reserve--an eight year study.

http://www.wikidata.org/entity/Q44013160

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Young age does not protect aga ...... reserve--an eight year study.

@en

Young age does not protect aga ...... reserve--an eight year study.

@nl

type

label

Young age does not protect aga ...... reserve--an eight year study.

@en

Young age does not protect aga ...... reserve--an eight year study.

@nl

prefLabel

Young age does not protect aga ...... reserve--an eight year study.

@en

Young age does not protect aga ...... reserve--an eight year study.

@nl

P1433

Q44013160-B5B0FE97-8CCA-43A9-88E6-F0FFC37E313E

P1476

Q44013160-8ACD6ED0-090F-4CFC-9B21-3496CEBFFA2A

P2093

Q44013160-0775ABAC-5306-468F-AC9D-33DE45940649

Q44013160-123D6642-9CB7-47DE-B2C5-DA3CA2D4266A

Q44013160-6B63D82B-CE0C-4AE7-B7F6-98283F412A2B

Q44013160-7B47956A-D3DE-41C5-866A-BC9F494FFBF4

Q44013160-9191217D-67E7-45C3-ABE4-1F2DDC5C776A

P2860

Q44013160-16B71453-63DD-4CF4-A063-FD73DF98CF1D

Q44013160-2F17C274-9CA5-43EF-B142-926059E1F4DD

Q44013160-35441751-9F84-4CB7-A1A0-C7F326FE555C

Q44013160-48650E4B-275D-435F-94F7-7988D993D6F4

Q44013160-4C9E9BE8-8415-43CC-802A-C7ED83E04CB9

Q44013160-53D824D9-DAA2-4045-AC31-65173AA19E16

Q44013160-5545ACBC-B559-4130-8768-433374D91D62

Q44013160-59079BE0-50E0-4762-98EB-E3D617D96872

Q44013160-6596B355-374C-44FC-BB7A-759D874688BC

Q44013160-73BA3ACF-BD33-4D26-B48D-36A6EF0525BE

P304

Q44013160-20AF8F50-A132-4EE5-A855-993403667590

P31

Q44013160-C5113B16-6D7A-4B1D-A4BB-765B27551428

P356

Q44013160-C230A2FF-1131-4AB2-8015-32C636503517

P407

Q44013160-3D591C91-BA25-4D20-8600-CC2D110219EE

P433

Q44013160-BD716AE7-BF40-4086-87D9-9211728F0E74

P478

Q44013160-02615BE9-EEFB-4EB2-BAB7-07CF8CF0466C

P577

Q44013160-F8FFACCF-89FE-4C75-B547-973C26018C34

P5875

Q44013160-8423734C-781C-4603-A2DE-0D8B5267D4FB

P698

Q44013160-22B008FA-2E0C-4BF8-AE3E-598D3408B3DA

P356

P1433

Human Reproduction

P1476

Young age does not protect aga ...... reserve--an eight year study.

@en

P2093

Alison Taylor

http://www.w3.org/2001/XMLSchema#string

Peter Braude

http://www.w3.org/2001/XMLSchema#string

Roger Hart

http://www.w3.org/2001/XMLSchema#string

Tarek El-Toukhy

http://www.w3.org/2001/XMLSchema#string

Yacoub Khalaf

http://www.w3.org/2001/XMLSchema#string

P2860

The role of genetic factors in age at natural menopause

Incidence of chromosomal abnormalities from a morphologically normal cohort of embryos in poor-prognosis patients

Follicular depletion during the menopausal transition.

Genes control the cessation of a woman's reproductive life: a twin study of hysterectomy and age at menopause.

Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause.

Poor oocyte quality rather than implantation failure as a cause of age-related decline in female fertility.

The cumulative embryo score: a predictive embryo scoring technique to select the optimal number of embryos to transfer in an in-vitro fertilization and embryo transfer programme.

Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders.

Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization.

Addition of GnRH antagonist in cycles of poor responders undergoing IVF.

P304

1519-1524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HUMREP/17.6.1519

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11331417

http://www.w3.org/2001/XMLSchema#string

P698

12042271

http://www.w3.org/2001/XMLSchema#string